How we treat NK/T-cell lymphomas

Table 3 Outcome of patients with NK/T-cell lymphomas treated with asparaginase-containing regimens

Regimens	Status	Stage	ORR	CR (%)	PFS	OS	References
VIDL + RT	Newly diagnosed	I/II	90%	87	5 year: 60%	5 year: 73%	[61]
LVP + RT	Newly diagnosed	I/II	89%	81	5 year: 64%	5 year: 64%	[64]
GELOX + RT	Newly diagnosed	I/II	96%	74	5 year: 74%	5 year: 85%	[67]
P-GEMOX [+ RT for stage I/II]	Newly diagnosed	I/II	94%	80	2 year: 77%	2 year: 83%	[68]
	Newly diagnosed	I/II	94%	64	3 year: 66%	3 year: 81%	[69]
	Relapsed/refractory		81%	52	3 year: 24%	3 year: 58%	[76]
DICE-L-asp	Newly diagnosed	I/II	100%	91	5 year: 82%	5 year: 89%	[70]
MESA	New diagnosed	I/II	92%	89	2 year: 89%	2 year: 92%	[30]
SMILE [+ RT for stage I/II]	Newly diagnosed	I/II	90%	69	Not reported		[73]
	Newly diagnosed	III/IV	Not reported	54	4 year: 60%	5 year: 47%
	Relapsed/refractory		77%	66	4 year: 68%	5 year: 52%
DDGP	Newly diagnosed	III/IV	95%	71	1 year: 86%	1 year: 90%	[77]
AspaMetDex	Relapsed/refractory		78%	61	2 year: 40%	2 year: 40%	[74]
MEDA	Relapsed/refractory		77%	61	1 year: 62%	1 year: 69%	[75]
GELAD	Newly diagnosed	I/II	94%	92	2 year: 90%	2 year: 94%	[71]

ORR: Overall response rate; CR: complete remission; PFS: progression-free survival; OS: overall survival; RT: radiotherapy; VIDL: etoposide, ifosfamide, dexamethasone, L-asparaginase; LVP: L-asparaginase, vincristine, prednisolone; GELOX: gemcitabine, L-asparaginase, oxaliplatin; P-GEMOX: pegaspargase, gemcitabine, oxaliplatin; DICE-L-asp: dexamethasone, ifosfamide, cisplatin, etoposide, L-asparaginase; MESA: methotrexate, etoposide, dexamethasone, pegaspargase; SMILE: dexamethasone, methotrexate, ifosfamide, L-asparaginase, etoposide; DDGP: dexamethasone, gemcitabine, cisplatin, pegaspargase; AspaMetDex: L-asparaginase, methotrexate, dexamethasone; MEDA: methotrexate, etoposide, dexamethasone and pegylated asparaginase; GELAD: gemcitabine, etoposide, pegasparaginase, dexamethasone

ISSN: 1756-8722